Brain Scientific Inc. (BRSF) Launches Latest Version of NeuroCap at Largest Global Conference for Neuro Specialists
- BRSF presented a new version of NeuroCap(TM), a revolutionary disposable EEG headset
- Latest version presented to international medical audience includes velcro enhancements for better adhesion
- Brain Scientific appears well placed to capitalize on growing need for neurodiagnostic procedures
Brain Scientific (OTCQB: BRSF) a neurology-focused medical device company, presented updates on its proprietary brain diagnostics technology at AES2020, the virtual annual meeting of the American Epilepsy Society, the world’s largest scientific meeting focused on epilepsy and clinical neurophysiology. BRSF released the latest version of its disposable electroencephalogram (“EEG”) device in October 2020: the NeuroCap with velcro enhancements, which provide better adhesion, ensuring easy application by any medical professional.
NeuroCap may provide significant benefits to healthcare providers because it can be easily applied without special training. The demand for EEG testing has been growing, but specialized EEG technologists are needed to perform the traditional diagnostic procedure. With NeuroCap, any clinical staff, including nurses and medical assistants can apply EEG cap in five minutes or less to expedite the EEG testing.
EEG testing is essential in medical care for patients diagnosed with epilepsy. Although almost 4% of people in the United States are diagnosed with epilepsy, BRSF data indicate that only 254 of 6,210 hospitals are level 4 epilepsy centers, which are medical facilities providing the highest level of care to epilepsy patients and equipped with 24/7 EEG services. The potential of this easy-to-use, cost-effective device to disrupt the slow and cumbersome EEG device space is particularly valuable in the current environment, which has seen an increase in the demand for brain diagnostics as a result of COVID-19.
In addition, emerging research is showing that COVID-19 can cause neurological damage, necessitating brain diagnostic procedures, increasing demand for EEG. Any opportunity to replace inefficient and expensive brain diagnostics procedures with innovative solutions that require less time may ease this built-up pressure.
As an FDA-cleared, easy-to-use, rapid EEG device that can provide results in minutes, the NeuroCap can help bridge that widening gap in the neurological devices market. Committed to closing this gap, Brain Scientific is providing further enhancements of its NeuroCap, including the newest version with velcro adhesions for easier and faster diagnostics, potentially saving time necessary to complete the procedure for each patient. Brain Scientific is dedicated to making the once time-consuming diagnostic process easier for medical staff and more comfortable for patients with each improvement.
For more information, visit the company’s website at www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://nnw.fm/BRSF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- BRSF presented a new version of NeuroCap(TM), a revolutionary disposable EEG headset
- Latest version presented to international medical audience includes velcro enhancements for better adhesion
- Brain Scientific appears well placed to capitalize on growing need for neurodiagnostic procedures
Brain Scientific (OTCQB: BRSF) a neurology-focused medical device company, presented updates on its proprietary brain diagnostics technology at AES2020, the virtual annual meeting of the American Epilepsy Society, the world’s largest scientific meeting focused on epilepsy and clinical neurophysiology. BRSF released the latest version of its disposable electroencephalogram (“EEG”) device in October 2020: the NeuroCap with velcro enhancements, which provide better adhesion, ensuring easy application by any medical professional.
NeuroCap may provide significant benefits to healthcare providers because it can be easily applied without special training. The demand for EEG testing has been growing, but specialized EEG technologists are needed to perform the traditional diagnostic procedure. With NeuroCap, any clinical staff, including nurses and medical assistants can apply EEG cap in five minutes or less to expedite the EEG testing.
EEG testing is essential in medical care for patients diagnosed with epilepsy. Although almost 4% of people in the United States are diagnosed with epilepsy, BRSF data indicate that only 254 of 6,210 hospitals are level 4 epilepsy centers, which are medical facilities providing the highest level of care to epilepsy patients and equipped with 24/7 EEG services. The potential of this easy-to-use, cost-effective device to disrupt the slow and cumbersome EEG device space is particularly valuable in the current environment, which has seen an increase in the demand for brain diagnostics as a result of COVID-19.
In addition, emerging research is showing that COVID-19 can cause neurological damage, necessitating brain diagnostic procedures, increasing demand for EEG. Any opportunity to replace inefficient and expensive brain diagnostics procedures with innovative solutions that require less time may ease this built-up pressure.
As an FDA-cleared, easy-to-use, rapid EEG device that can provide results in minutes, the NeuroCap can help bridge that widening gap in the neurological devices market. Committed to closing this gap, Brain Scientific is providing further enhancements of its NeuroCap, including the newest version with velcro adhesions for easier and faster diagnostics, potentially saving time necessary to complete the procedure for each patient. Brain Scientific is dedicated to making the once time-consuming diagnostic process easier for medical staff and more comfortable for patients with each improvement.
For more information, visit the company’s website at www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://nnw.fm/BRSF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
